Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Paclitaxel derivatives developed at Bristol-Myers Squibb

July 11, 1997

Sparta's Spartaject busulfan enters phase I

July 11, 1997

GeneMedicine and UCSF enter into gene therapy collaboration

July 11, 1997

Banyu claims farnesyltransferase inhibitors

July 11, 1997

New antitumor taxanes from Yakult Honsha

July 11, 1997

Hycamtin launched in Canada

July 10, 1997

Kyowa Hakko develops cell adhesion inhibitors

July 10, 1997

Immunex receives approval to market paclitaxel in Canada

July 9, 1997

Novel antitumor agents from Sanwa Kagaku

July 9, 1997

CarboMed licenses broad-spectrum anticancer agent to Zeneca

July 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...